Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Hadassah Medical Organization.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Hadassah Medical Organization
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00149006
First received: September 7, 2005
Last updated: March 13, 2007
Last verified: September 2005
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The present protocol is designed to investigate the potential application of allogeneic cell-mediated immunotherapy in metastatic solid tumors similarly to the well established graft versus leukemia (GVL) effects in patients with hematologic malignancies.
Patients with metastatic solid tumors resistant to conventional modalities will be eligible to participate in a treatment program based on the administration of non-myeloablative immunotherapy (i.e. fludarabine, Cytoxan) followed by interferon injections; subsequently the patients will be treated with mismatched alloreactive donor lymphocytes activated in vitro and in vivo with rIL-2. The aim of this study is based on the recognition of foreign tumor cell surface alloantigens.
| Condition | Intervention | Phase |
|---|---|---|
|
Tumors |
Procedure: Cell therapy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | Tumor-Selective and Systemic Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With rIL-2 and Non-Myeloablative Stem Cell Transplantation |
Resource links provided by NLM:
Further study details as provided by Hadassah Medical Organization:
Primary Outcome Measures:
- Study the feasibility, toxicity, and response rate of allogeneic cell therapy induced by selective intra-lesional and systemic administration of mismatched alloreactive lymphocytes in patients with metastatic cancer
Secondary Outcome Measures:
- Study the feasibility, toxicity, and response to treatment with allogeneic mini-transplant using sibling donors in patients with metastatic cancer
| Estimated Enrollment: | 100 |
| Study Start Date: | December 1996 |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Consenting patients (age < 70) will be eligible for participation in the study involving selective anti-tumor immunotherapy provided the following criteria are met:
- Evidence of cancer not expected to be cured with conventional modalities
- Pediatric patients: Chemotherapy-resistant neuroblastoma stage 4 and sarcomas. Adult patients: Metastatic breast cancer, malignant melanoma, renal cell cancer and selected cases of ovarian cancer, gastrointestinal cancer, small-cell and non-small cell lung cancer with non-bulky metastatic disease, and metastatic prostate cancer.
- Patients with measurable disease evaluable for response with anticipated life expectancy > 3 months.
- Patients must be > 2 weeks off of anti-cancer or potentially immunosuppressive treatment.
- Adequate ambulatory performance status (Karnofsky > 80%; ECOG 0-1) to enable outpatient treatment.
- Compliant and cooperative patients anticipated to be evaluable for response according to the investigator's assessment.
- HLA-compatible (fully matched or single locus mismatched) donor available for allogeneic stem cell transplantation.
Exclusion Criteria:
- Patients with bulky disease or patients with brain metastases resistant to chemo-radiotherapy.
- Patients with a significant history or current evidence of potentially severe cardiovascular or lung disease, or other disease or clinical condition that may not permit accomplishing the planned treatment or drawing conclusions.
- Hepatic and/or renal failure.
- Evidence of serious active infection requiring antibiotic therapy.
- Pregnancy.
- Contraindication for donation due to donor disease: HIV-1; hepatitis B surface antigen (HBsAg) positivity.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00149006
Contacts
| Contact: Shimon Slavin, MD | +972-2-6776561 | slavin@cc.huji.ac.il |
Locations
| Israel | |
| Hadassah Medical Organization | Recruiting |
| Jerusalem, Israel, 91120 | |
| Contact: Shimon Slavin, MD +972-2-6776561 slavin@hadassah.org.il | |
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
| Principal Investigator: | Shimon Slavin, MD | Hadassah Medical Organization |
| Study Director: | Reuven Or, MD | Hadassah Medical Organization |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00149006 History of Changes |
| Other Study ID Numbers: | 271296-HMO-CTIL |
| Study First Received: | September 7, 2005 |
| Last Updated: | March 13, 2007 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Hadassah Medical Organization:
|
Metastatic solid tumor Mismatch allogeneic cell mediated immunotherapy |
Additional relevant MeSH terms:
|
Interleukin-2 Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 19, 2013